Streetbeat News

ADC

Agree Realty Corporation

https://www.agreerealty.com

Industry

REIT - Retail

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Open

72.29

Mkt cap

7.5B

Volume

606K

High

72.88

P/E Ratio

39.16

52-wk high

78.39

Low

71.88

Div yield

0.04

52-wk low

54.28

Zai Lab Limited has received Orphan Drug Designation from the U.S. FDA for its drug ZL-1310, a DLL3 antibody-drug conjugate, for the treatment of small cell lung cancer. This designation highlights the potential of ZL-1310 to address the urgent need for innovative treatments in this area.

Portfolio Pulse from

January 23, 2025 | 4:30 am

Agree Realty (ADC) remains a strong investment despite a REIT selloff due to rising Treasury yields. The company boasts 12.8% revenue growth, 99.6% leased properties, and a solid tenant base, supporting a 4.3% dividend yield. ADC's stable financials and $2 billion liquidity provide stability amid high Fed rates.

Portfolio Pulse from

January 17, 2025 | 2:15 pm

Joey Agree, CEO of Agree Realty, discussed the increasing risks for commercial properties and recent retail trends on CNBC's The Exchange.

Portfolio Pulse from

January 14, 2025 | 7:30 pm

Elevation Oncology has initiated dosing in a Phase 1 trial for its Claudin 18.2 ADC EO-3021, in combination with other drugs, targeting advanced gastric/GEJ cancer. Initial data is expected by late 2025 or early 2026. The company is also progressing with its HER3 ADC EO-1022, planning to present preclinical data in 2025 and file an IND application in 2026.

Portfolio Pulse from

January 13, 2025 | 12:45 pm

Biohaven Ltd. and Merus N.V. have announced a collaboration to co-develop three novel bispecific antibody drug conjugates (ADCs) using Merus' Biclonics® technology and Biohaven's ADC platform.

Portfolio Pulse from

January 13, 2025 | 1:15 am

US equity markets fell sharply as interest rates neared multi-decade highs due to strong employment data and rising energy prices. Real estate equities, particularly REITs, were hit hard as rate cut expectations diminished.

Portfolio Pulse from

January 12, 2025 | 2:15 pm

The article highlights three reliable monthly dividend-paying stocks that provide consistent cash flow and financial stability for income investors. These stocks are praised for their stability and growth potential, making them ideal for income-focused portfolios.

Portfolio Pulse from

January 11, 2025 | 12:45 pm

Agree Realty Corporation (NYSE: ADC) will release its Q4 and full year 2024 earnings on February 11, 2025, after market close.

Portfolio Pulse from

January 07, 2025 | 9:15 pm

Agree Realty Corporation (NYSE: ADC) announced its 2024 investment activity and provided a 2025 investment outlook with guidance of $1.1 billion to $1.3 billion. The company has over $2.0 billion in liquidity, indicating a strong balance sheet.

Portfolio Pulse from

January 06, 2025 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.